OVERVIEW

A Virtual Reality Tour of Nonstatin LDL-C-lowering Agents that Decrease Cardiovascular Risk for Patients with Persistent Hypercholesterolemia is organized by Med Learning Group and will be held from Oct 15, 2018 - Oct 15, 2019.

The target audience for this medical event is intended for lipidologists, cardiologists, endocrinologists, and other healthcare professionals involved in the management of patients at high risk for cardiovascular disease (CVD) due to hypercholesterolemia.This CME Conference has been approved for a maximum of 1 AMA PRA Category 1 Credits.

Program Overview:
This case-based enduring activity will cover the long-term treatment and management of cardiovascular disease (CVD) due to hypercholesterolemia.

Learning Objectives:
After completing the CME activity, learners should be better able to:
• Review evidence demonstrating that lowering LDL-C can reduce the risk for CVD in patients with persistently elevated cholesterol levels
• Discuss the latest clinical trial data available on nonstatin LDL-C–lowering agents and their position in treatment regimens for patients with elevated LDL-C levels
• Describe best practices for detection and management of persistently elevated LDL-C levels in patients at high-risk for CVD
• Explain the pharmacoeconomic data on the use of nonstatin lipid lowering drugs and their managed care implications